Treating Graves’ Disease with Ablation: New Perspectives from Dr. Alireza Falahati

Treating Graves’ Disease with Ablation: New Perspectives from Dr. Alireza Falahati

In a recent interview with Philip James, host of the Doctor Thyroid and RFAMD podcasts, Dr. Alireza Falahati, a renowned endocrinologist from Utah, provided exciting insights from the TNT conference held in Reggio Emilia, Italy. The primary focus of the conversation was a groundbreaking development in the treatment of Graves’ disease: the possibility of treating the entire thyroid gland with radiofrequency ablation (RFA), a potential game-changer in the management of this condition.

Graves’ disease is an immune system disorder that results in the overproduction of thyroid hormones, also known as hyperthyroidism. The conventional treatment strategies for Graves’ disease include antithyroid medications, radioactive iodine therapy, and thyroid surgery. While effective, these treatments often come with potential side effects and risks, which highlights the need for novel, less invasive treatment options.

Radiofrequency ablation (RFA) involves using heat generated from high-frequency alternating currents to ablate or destroy abnormal tissue. This technique has found applications in the treatment of various medical conditions, including certain types of cancers. Dr. Falahati’s revelation about the potential use of RFA to treat the entire thyroid gland could significantly transform the therapeutic landscape for Graves’ disease, offering a non-invasive and low-risk treatment alternative.

During the interview, Dr. Falahati expressed his enthusiasm about this novel approach, stating, “this is a new revelation. It is amazing. It’s going to be really a game-changer and change our whole approach to patients with Graves’ disease.” The possibility of using RFA for the treatment of Graves’ disease carries the promise of enhancing the quality of life for patients and instilling new hope for better disease management.

Dr. Falahati also stressed the value of scientific conferences like TNT, where experts worldwide convene to share knowledge and foster innovative discussions. He lauded the conference for facilitating learning experiences and supporting the growth of transformative treatment approaches.

As this method’s adoption is still in the early stages, it’s yet to be seen how quickly it will become a mainstream treatment option for Graves’ disease. However, the optimism and anticipation echoed by Dr. Falahati signify a promising future in the field of endocrinology.

In conclusion, Dr. Falahati expressed his gratitude towards the organizers and participants of the TNT conference, highlighting his eagerness to attend next year’s event. The insights gained from such platforms continually contribute to the advancement of medical science, paving the way for more effective, less invasive treatments for complex diseases like Graves’. Radiofrequency ablation promises to be a groundbreaking addition to the therapeutic options, potentially revolutionizing patient care and improving their quality of life.

View Dr. Alireza Falahati’s Full Profile:


About Dr. Alireza Falahati

Alireza Falahati, MD, FACE, is a board-certified endocrinologist and the founder and medical director of Utah Endocrinology Associates in Salt Lake City, American Fork, and Ogden, Utah. At his practice, Dr. Falahati treats a full range of endocrine disorders, with a specialization in diabetes, osteoporosis, and thyroid disease.
After graduating from the University of Vienna Medical School in Vienna, Austria, in 1994, Dr. Falahati relocated to Pennsylvania to continue his education. He completed his internship at the Reading Hospital and Medical Center in Reading, Pennsylvania, and then went on to finish his internal medicine residency and chief residency at Hennepin County Medical Center in Minneapolis, Minnesota.

Dr. Alireza Falahati proudly received his training as a sub-specialist in the field of endocrinology, diabetes, and metabolism at the prestigious Mayo Clinic in Rochester, Minnesota. Since leaving the Mayo Clinic in 2001, he has received many national and international awards for his research. He has also published articles in respected medical and scientific journals and books.

Dr. Alireza Falahati has given numerous lectures and interviews on topics related to osteoporosis, diabetes, pre-diabetes, and thyroid disorders.
Before founding Utah Endocrinology Associates, Dr. Alireza Falahati was the chairman of the Institutional Review Board overseeing research activities and the medical director of the Diabetes Center at St. Mark’s Hospital in Salt Lake City, Utah.

Dr. Alireza Falahati is the current chapter president of the American Association of Clinical Endocrinologists and the founder and director of Utah Endocrinology Associates and the Utah Osteoporosis Foundation.

View Full Profile:

About Philip James

In 2013, his laryngeal nerve was severed, shoulder nerve damaged, parathyroids ruined, and residual cancer left behind — all for a 1 cm thyroid nodule.
Later, a vocal cord implant was inserted to help him speak.

The word he uses to describe his work as patient advocate is, ‘tonglen’. Or, using his pain and hardship to help others.


RFAMD is solely dedicated to helping healthcare organizations build deeper, enduring relationships with patients. Our team brings together expertise and insights to create enterprise-wide solutions that transform the patient experience.

With years of experience in understanding the patient’s journey, we can help healthcare organizations thrive in today’s patient-centered healthcare market. Our range of solutions includes smart, measurable patient acquisition programs, physician marketing touch-points that drive referrals into priority service lines, and credible, easy-to-digest content at the point of care and beyond, in patients’ preferred formats and languages.

We also provide brand strategies that increase patient preference and physician referrals and differentiate your brand in the market through reputation-building tools.

Our commitment is to enable providers and payers to deliver personalized care by activating, educating, and motivating patients to prioritize their health every day. As your strategic partner, we combine our unique capabilities and industry expertise to better engage patients at every step of their health journey.

Our goal is to help healthcare organizations achieve stronger patient and member outcomes, sustained improvements in brand reputation, measurable gains in market share, and increased revenue.

Content on the RFAMD and Doctor Thyroid with Philip James websites and podcasts is for informational purposes only and not a substitute for professional medical advice. See our full Legal Disclaimer for details.